Search Results

Audax Private Equity (“Audax”), a leading alternative investment manager and capital partner, announced today that it has made a growth investment in Pyramid Laboratories, Inc. (“Pyramid” or the “Company”) to support the continued growth of the Company’s clinical and commercial biologics and advanced therapeutics manufacturing and service operations.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Pyramid, a leading large molecule drug product contract development and manufacturing organization (“CDMO”), announced the appointment of Amy Driver as Vice President of Business Development and Peter Buzy to the Board of Directors.

Eurofins CDMO Alphora Inc., a global Contract Development & Manufacturing Organization and part of the international network of Eurofins laboratories, is pleased to announce a significant expansion of its Drug Product Analytical Services Laboratory, increasing its footprint three-fold.

Pyramid Biosciences, Inc. has announced its participation this week in the B. Riley Securities 3rd Annual Oncology Conference.

Mesa Laboratories, Inc. will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 as previously communicated.

bioLytical Laboratories Inc., a global leader in rapid diagnostic tests, proudly announces the immediate availability of its INSTI® HCV Antibody Test in the Australian market.

Kraig Biocraft Laboratories, Inc., announces that it has expanded its production of spider silk with the creation of the next generation of BAM-1 hybrid.

Mesa Laboratories, Inc. will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 31, 2024.